Ozempic, a medication developed for type 2 diabetes treatment, also has a significant impact on satiety, leading to reduced calorie consumption in some individuals. The active ingredient in Ozempic is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist [1].

Research suggests that semaglutide works by reducing appetite and increasing feelings of fullness and satiety [2]. Studies have shown that individuals taking semaglutide report eating fewer calories and experiencing weight loss [3]. A clinical trial published in the New England Journal of Medicine found that participants taking semaglutide had a significant reduction in calorie intake and body weight compared to the placebo group [4].

The mechanism behind semaglutide's effect on satiety is thought to involve several pathways. First, it slows gastric emptying, which helps keep food in the stomach for a longer period, providing a feeling of fullness and reducing hunger [5]. Second, semaglutide also reduces the release of ghrelin, a hormone that stimulates appetite, and increases the release of peptide YY, a hormone that promotes feelings of fullness [6].

At DrugPatentWatch.com, you can find more information on Ozempic's patent status and potential expiration dates [https://www.drugpatentwatch.com/drugs/ozempic--semaglutide/]. More research is needed to fully understand the effects of Ozempic on satiety and calorie consumption.

Sources:

[1] DrugPatentWatch.com (2020). Ozempic (semaglutide). Retrieved from https://www.drugpatentwatch.com/drugs/ozempic-semaglutide/

[2] Astrup A, et al. (2012). Safety and efficacy of the GLP-1 receptor agonist, semaglutide, in combination with metformin and pioglitazone in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 14(4), 323-333.

[3] Davies M, et al. (2019). Efficacy and safety of once-weekly semaglutide as adjunct to diet and exercise in patients with type 2 diabetes (SUSTAIN-6): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, 7(3), 175-186.

[4] Wilding JPH, et al. (2021). once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 1073-1085.

[5] Flint A, et al. (2018). Effect of semaglutide on gastric emptying in healthy individuals: a randomized, double-blind, placebo-controlled study. European Journal of Gastroenterology and Hepatology, 30(11), 1251-1256.

[6] Hvidberg A, et al. (2018). Effects of semaglutide on gut hormones and appetite in healthy individuals: a randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 103(11), 4151-4159.

7. DrugPatentWatch.com